Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Finance leases — Weighted-average discount rate by Year
Finance leases — Weighted-average discount rate (%) (%)
Moderna Finance leases — Weighted-average discount rate: 590.0% in FY2025, unchanged from a year earlier.
Latest, FY2025
590.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
590.0% in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 10 (Leases).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Finance leases — Weighted-average discount rate (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 590.0% | 0.0 pts | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 590.0% | +170.0 pts | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 420.0% | +60.0 pts | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 360.0% | +50.0 pts | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 310.0% | -1000.0 pts | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 1,310.0% | -410.0 pts | Form 10-K (filed 2021-02-26) ↗ |
| FY2019 | Dec 31, 2019 | 1,720.0% | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Moderna Finance leases — Weighted-average discount rate (%), annual FY2019–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/fin-lease-disc-rate
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.